Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt 0.22
MNKD's Cash to Debt is ranked higher than
52% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. MNKD: 0.22 )
MNKD' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 0.22

F-Score: 3
Z-Score: -10.36
M-Score: -4.09
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
Operating margin (%) -419885.71
MNKD's Operating margin (%) is ranked lower than
52% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. MNKD: -419885.71 )
MNKD' s 10-Year Operating margin (%) Range
Min: -3073570   Max: -15273.62
Current: -419885.71

-3073570
-15273.62
Net-margin (%) -483902.86
MNKD's Net-margin (%) is ranked lower than
52% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -69.57 vs. MNKD: -483902.86 )
MNKD' s 10-Year Net-margin (%) Range
Min: -2931900   Max: -14799.08
Current: -483902.86

-2931900
-14799.08
ROA (%) -94.22
MNKD's ROA (%) is ranked higher than
54% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -21.69 vs. MNKD: -94.22 )
MNKD' s 10-Year ROA (%) Range
Min: -393.74   Max: -52.52
Current: -94.22

-393.74
-52.52
ROC (Joel Greenblatt) (%) -113.35
MNKD's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -217.20 vs. MNKD: -113.35 )
MNKD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -570.67   Max: -71.09
Current: -113.35

-570.67
-71.09
EBITDA Growth (%) -25.50
MNKD's EBITDA Growth (%) is ranked higher than
62% of the 621 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. MNKD: -25.50 )
MNKD' s 10-Year EBITDA Growth (%) Range
Min: -43   Max: 10.9
Current: -25.5

-43
10.9
EPS Growth (%) -23.10
MNKD's EPS Growth (%) is ranked higher than
67% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. MNKD: -23.10 )
MNKD' s 10-Year EPS Growth (%) Range
Min: -42.9   Max: 7.6
Current: -23.1

-42.9
7.6
» MNKD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

MNKD Guru Trades in Q3 2013

Murray Stahl 57,451 sh (New)
Steven Cohen 231,900 sh (+8.99%)
» More
Q4 2013

MNKD Guru Trades in Q4 2013

Murray Stahl 106,211 sh (+84.87%)
Steven Cohen 143,117 sh (-38.29%)
» More
Q1 2014

MNKD Guru Trades in Q1 2014

Murray Stahl 134,495 sh (+26.63%)
Steven Cohen 103,800 sh (-27.47%)
» More
Q2 2014

MNKD Guru Trades in Q2 2014

Paul Tudor Jones 29,250 sh (New)
Jim Simons 1,769,800 sh (New)
Murray Stahl 73,850 sh (-45.09%)
» More
» Details

Insider Trades

Latest Guru Trades with MNKD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-03-31 Sold Out 0.01%$2.31 - $3.56 $ 5.65106%0
Jean-Marie Eveillard 2012-12-31 New Buy0.01%$1.85 - $2.83 $ 5.65162%800000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
EV-to-EBIT -16.12
MNKD's EV-to-EBIT is ranked higher than
56% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MNKD: -16.12 )
MNKD' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -16.12

Current Ratio 0.38
MNKD's Current Ratio is ranked lower than
51% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. MNKD: 0.38 )
MNKD' s 10-Year Current Ratio Range
Min: 0.12   Max: 12.24
Current: 0.38

0.12
12.24
Quick Ratio 0.38
MNKD's Quick Ratio is ranked higher than
50% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. MNKD: 0.38 )
MNKD' s 10-Year Quick Ratio Range
Min: 0.12   Max: 12.24
Current: 0.38

0.12
12.24

Valuation & Return

vs
industry
vs
history
Forward Rate of Return (Yacktman) -52.06
MNKD's Forward Rate of Return (Yacktman) is ranked higher than
63% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -10.16 vs. MNKD: -52.06 )
MNKD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -52.06

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NNF1.Germany
MannKind Corporation, a development stage biopharmaceutical company, was founded in 1991. The Company is engaged in the discovery, development and commercialization of therapeutic products for diseases such as diabetes. Its product candidate, AFREZZA inhalation powder, is an ultra insulin therapy that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. The Company also develops MKC1106-MT, an investigational cancer immunotherapy product, which is in Phase II clinical trials; and MKC204, which is in preclinical development stage for the treatment of malignancies and inflammatory diseases.
» More Articles for MNKD

Headlines

Articles On GuruFocus.com
Roche to Acquire InterMune and Deliver Hope to Patients Worldwide Aug 25 2014 
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Evaluating MannKind (MNKD) & Sanofi (SNY) Agreement for Afrezza Aug 15 2014 
There is a Tide in the Affairs of MannKind: When Taken At the Flood, Will Lead to Fortune Aug 14 2014 
What This Upcoming Monday Means For MannKind Shareholders Aug 08 2014 
Shareholders To Inhale Relief As MannKind Found Its Bright Insulin Supply Partner Amphastar Aug 06 2014 
Shareholders To Inhale Relief As MannKind Found Its Bright Insulin Supply Partner Amphastar Aug 06 2014 
Osiris Stem Cells To Compliment Mannkind's Afrezza In Disrupting Diabetes Market Jul 29 2014 
Mannkind Corporation: Safe Labeling, Incentivized Spirometry and Experts Votes of Confidence Jul 25 2014 


More From Other Websites
1:14 am Mannkind announces receipt of $150 mln licensing upfront payment from Sanofi (Sep 30 2014
MannKind Announces Receipt of $150 Million Licensing Upfront Payment Sep 29 2014
MANNKIND CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Sep 29 2014
The Zacks Analyst Blog Highlights: Con-way, Covenant Transportation Group, Old Dominion Freight... Sep 29 2014
MannKind and Sanofi Complete Afrezza Collaboration Deal Sep 26 2014
[video] Stocks Start the Day Lower as Investors Assess Latest Economic Data Sep 25 2014
US STOCKS-MannKind, Magnum Hunter among premarket actives Sep 25 2014
MANNKIND CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 24 2014
MannKind Announces Closing of Global Licensing Agreement With Sanofi Sep 24 2014
Why You Shouldn't Bet Against MannKind (MNKD) Stock Sep 18 2014
MannKind Corporation to Present at Morgan Stanley Global Healthcare Conference Sep 02 2014
MannKind: Why Jefferies Says Buy Aug 27 2014
How Will MannKind (MNKD) Stock Respond to This Coverage Initiation? Aug 27 2014
Roche Buying InterMune for $8.3 Billion; Investors Want More Pharma Deals Aug 25 2014
Who's Next in the M&A Wave Aug 22 2014
MANNKIND CORP Financials Aug 19 2014
[video] MannKind Snares Sanofi, Intercept Soars & Southwest's Mexico Move Aug 15 2014
Blame MannKind's Fall on its Bloated Balance Sheet Aug 13 2014
What the Market is Telling MannKind Aug 13 2014
Did MannKind Find Right Afrezza Partner in Sanofi? Aug 12 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK